logo

KPRX

Kiora Pharmaceuticals
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 0
Sell signal 2
Significant Net Income Decline
EPS Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000

About KPRX

Kiora Pharmaceuticals, Inc.

A clinical-stage biotechnology company that develops the treatments for ophthalmic diseases

Pharmaceutical
12/26/2004
07/31/2015
NASDAQ Stock Exchange
12
12-31
Common stock
332 Encinitas Blvd., Suite 102, Encinitas, CA 92024
--
Kiora Pharmaceuticals, Inc., was incorporated as a Delaware corporation on December 26, 2004 under the name EyeGate Pharmaceuticals, Inc., and changed its name to Kiora Pharmaceuticals, Inc., effective November 8, 2021. The Company is a clinical stage specialty pharmaceutical company focused on the development and commercialization of therapies and drug delivery for the treatment of eye diseases.

Company Financials

EPS

KPRX has released its 2023 Q3 earnings. EPS was reported at -0.89, versus the expected -0.35, missing expectations. The chart below visualizes how KPRX has performed over recent quarters, highlighting trends in earnings surprises.

Forecast

Wall Street Opinions

Price Target

Volume Profile

Trade Flow Insight

Seasonals

Community Forum

Loading...

Related News

No articles available

Related Symbols

You can ask Aime